Clinical Trials

• Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

• Acute Lymphblastic Leukemia
• A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy (ACCL1931)

• Brain Cancer
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)

• Brain Tumor
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)

• Leukemia
• A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas

• Lymphomas
• A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase 1/2 Study to Evaluate the Safety and Efficacy of DR-01 in Adult Subjects with Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
• A phase 2 open-label, multicenter study evaluating the safety and efficacy of axicabtagene ciloleucel concomitant with prophylactic steroids in subjects with relapsed or refractory large b-cell lymphoma in the outpatient setting
• A Phase 1-2, Open-Label Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Activity of Tolinapant in Combination with Oral Decitabine/ Cedazuridine and Oral Decitabine/ Cedazuridine Alone in Subjects with Relapsed/Refractory Peripheral T-cell Lymphoma
• A Phase 1, Multicenter, Open-Label, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-413 in Adult Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer Agents in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• Fitness-adapted, pembrolizumab-based therapy for untreated classical Hodgkin lymphoma patients 60 years of age and above (cHL 001)
• A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT2527 as Monotherapy and in Combination with Zanubrutinib in Participants with Relapsed/Refractory Hematologic Malignancies
• A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)
• A Phase 3, Open-Label, Randomized Study to Compare the Efficacy and Safety of an Anti-CD20 X Anti-CD3 BiSpecific Antibody, Versus Investigator’s Choice in Previously Untreated Participants with Follicular Lymphoma (OLYMPIA-1)
• A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
• Study for Patients with Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma (CTCL) Comparing an Investigational Combination of Pembrolizumab (Keytruda) with Decitabine and/or Pralatrexate (PTCL 002)
• Adults with Newly Diagnosed Mantle Cell Lymphoma invited to be in a research study comparing three chemotherapy regimens
• A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission
• A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-333 in Adult Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
• A Phase 3 Open-label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321)
• A randomized, open-label study evaluating the efficacy and safety of cemacabtagene ansegedleucel in participants with minimal residual disease after response to first line therapy for large B-cell lymphoma (ALPHA3)

• Pediatric Cancers: Hodgkin's Disease
• A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy With Immuno-Oncology Therapy for Children and Adults With Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma (AHOD2131)

• Pediatric Cancers: Lymphoma
• A Randomized Trial of Levocarnitine Prophylaxis to Prevent Asparaginase-Associated Hepatotoxicity in Adolescents and Young Adults Receiving Acute Lymphoblastic Leukemia Therapy (ACCL1931)

• Peripheral T-Cell Lymphoma (PTCL)
• Study for Patients with Peripheral T-Cell Lymphoma (PTCL) or Cutaneous T-Cell Lymphoma (CTCL) Comparing an Investigational Combination of Pembrolizumab (Keytruda) with Decitabine and/or Pralatrexate (PTCL 002)
• Study for Patients with Peripheral T-Cell Lymphoma Comparing an Investigational Combination with Standard Treatment

• Primary Central Nervous System Lymphoma (PCNSL)
• Study for Adults with Primary Central Nervous System Lymphoma (PCNSL)

• Solid Tumors
• A Phase 1a, Dose Escalation, Safety and Tolerability Study of NX-1607, a Casitas B-lineage lymphoma proto-oncogene (CBL-B) inhibitor, in Adults with Advanced Malignancies, with Phase 1b Expansion in Select Tumor Types

• Stem Cell Transplant
• A phase 2, open-label, single-arm, multicohort, multicenter trial to evaluate the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory indolent B-cell non-hodgkin lymphoma (NHL)

• Uterine Cancer
• A Phase 3, Randomized, Placebo-Controlled, Double-Blind, Multicenter Trial for Selinexor in Maintenance Therapy after Systemic Therapy for Patients with P53 wild-type, Advanced or Recurrent Endometrial Carcinoma